As a co-founder of Cybrexa, Per Hellsund rejoined old colleagues Kevin Didden, Cybrexa board chair, and Kevin Rakin, a director. They are seeking to leverage research developed at Yale University’s School of Medicine by Dr. Ranjit Bindra, Cybrexa’s chief scientific advisor and scientific co-founder.
Cybrexa’s proprietary alphalex platform selectively delivers powerful anticancer agents directly into tumor cells. The key is peptide technology developed by Dr. Donald Engelman, Higgins Professor of biochemistry at Yale and a Guggenheim Fellow, and exclusively licensed by Cybrexa. It allows alphalex to differentiate between tumors and healthy tissue, reducing toxic side effects.